


S/N 09/150813

PATENT



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant:	David J. Grainger et al.	Examiner:	Joseph Murphy
Serial No.:	09/150813	Group Art Unit:	1646
Filed:	September 11, 1998	Docket:	1543.002US1
Title:	COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE		

**INFORMATION DISCLOSURE STATEMENT**

MS RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Information Disclosure Statement considered.

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

DAVID J. GRAINGER ET AL.


By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
P.O. Box 2938  
Minneapolis, MN 55402  
(612) 373-6959

Date


September 25, 2003

By


  
Janet E. Embretson  
Reg. No. 39,665

**CERTIFICATE UNDER 37 CFR 1.8:** The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 25 day of September, 2003.

Name




Signature



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Sheet 1 of 2

Complete if Known

<b>Application Number</b>	09/150813
<b>Filing Date</b>	September 11, 1998
<b>First Named Inventor</b>	Grainger, David
<b>Group Art Unit</b>	1646
<b>Examiner Name</b>	Murphy, Joseph

Attorney Docket No: 1543.002US1

**US PATENT DOCUMENTS**

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
	US-5,571,713	11/05/1996	Lyle, et al.	435	240.2	05/27/1994
	US-5,770,609	06/23/1998	Grainger, D., et al.	514	319	06/07/1995

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T <sup>2</sup>
	WO-00/00821	01/06/2000	Ullman, E.	G01 N	33/48	
	WO-92/14455	09/03/1992	Kaplan, Oet al.	A61K	31/21	

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BUSINCO, L. , et al., "From Atopic Dermatitis to Asthma: The Risk Factors and Preventive Measures", <u>Pediatric Pulmonology, Supplement, 16, (1997),pp. 19-20</u>	
		ELSON, C. , et al., "Experimental Models of Inflammatory Bowel Disease", <u>Gastroenterology, 109, (1995),pp. 1344-1367</u>	
		FRECKER, M. , et al., "Immunological Associations in Familial and Non-Familial Alzheimer Patients and Their Families", <u>The Canadian Journal of Neurological Sciences, 21, (1994),pp. 112-119</u>	
		IVACKO, J. , et al., "Hypoxic-Ischemic Injury Induces Monocyte Chemoattractant Protein-1 Expression in Neonatal Rat Brain", <u>Journal of Cerebral Blood Flow and Metabolism, 17, (1997),pp. 759-770</u>	
		JIN, D. , et al., "Complement 4 Locus II Gene Deletion and DQA1*0301 Gene: Genetic Risk Factors for IgA Nephropathy and Henoch-Schonlein Nephritis", <u>Nephron, 73, (1996),pp. 390-395</u>	
		KARPUS, W. , et al., "An Important Role for the Chemokine Macrophage Inflammatory Protein-1alpha in the Pathogenesis of the T Cell-Mediated Autoimmune Disease., Experimental Autoimmune Encephalomyelitis", <u>The Journal of Immunology, (1995),pp. 5003-5010</u>	
		KUNKEL, S. , et al., "The role of chemokines in inflammatory joint disease", <u>Journal of Leukocyte Biology, 59, (1996),pp. 6-12</u>	
		LUCCHINETTI, C. , et al., "Risk factors for developing multiple sclerosis after childhood optic neuritis", <u>The American Academy of Neurology, 49, (1997),pp. 1413-1418</u>	
		MARONE, M. , et al., "Influence of body composition on the bone mass of post menopausal women", <u>Sao Paulo Medical Journal, 115(6), (1997),pp. 1580-1588</u>	
		MARRA, F. , et al., "Increased Expression of Monocyte Chemotactic Protein-1 during Active Hepatic Fibrogenesis", <u>American Journal of Pathology, 152, (1998),pp. 423-430</u>	

**EXAMINER****DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)


\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

<b>Application Number</b>	09/150813
<b>Filing Date</b>	September 11, 1998
<b>First Named Inventor</b>	Grainger, David
<b>Group Art Unit</b>	1646
<b>Examiner Name</b>	Murphy, Joseph

Sheet 2 of 2

Attorney Docket No: 1543.002US1

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		MCGEER, P. , et al., "The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases", <u>Brain Research Reviews</u> , 21, (1995),pp. 195-218	
		NALDI, L. , et al., "Dietary factors and the risk of psoriasis. Results of an Italian case-control study", <u>British Journal of Dermatology</u> , 134, (1996),pp. 101-106	
		ONO, K. , et al., "Prevention of Myocardial Reperfusion Injury in Rats by an Antibody against Monocyte Chemotactic and Activating Factor/Monocyte Chemoattractant Protein-1", <u>Laboratory Investigation</u> , 79, (1999),pp. 195-203	
		PAUL, WILLIAM E., "Fundamental Immunology", 3rd Edition, (1993),822-826	
		REWERS, M , et al., "Newborn screening for HLA markers associated with IDDM: Diabetes Autoimmunity Study in the Young (DAISY)", <u>Diabetologia</u> , 39, (1996),pp. 807-812	
		SPENCE, J. , "Advances in atherosclerosis", <u>Bailliere's Clinical Neurology</u> , 4(2), (1995),pp. 191-205	
		SUDA, T. , et al., "Modulation of Osteoclast Differentiation by Local Factors", <u>Bone</u> , 17(2), (1995),pp. 87S-91S	
		VERMA, M. , et al., "Chemokines in acute anterior uveitis", <u>Current Eye Research</u> , (1997),pp. 1202-1208	
		WATANABE, T. , et al., "Atherosclerosis and inflammation Mononuclear cell recruitment and adhesion molecules with reference to the implication of ICAM-1/LFA pathway in atherogenesis", <u>International Journal of Cardiology</u> , 66, (1998),pp. S45-S53	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached